|Articles|July 1, 2019
- Pharmaceutical Executive-07-01-2019
- Volume 39
- Issue 7
Pharmaceutical Executive, July 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Creating an ‘Unbossed’ Environment in the Workplacealmost 7 years ago
Proposed Rebates Rule Raises Tough Questionsalmost 7 years ago
Drug Formulary Decisions: Fixing a Broken Systemalmost 7 years ago
The Feasibility of Patient Insights Before Launchalmost 7 years ago
Compliance Disruptorsalmost 7 years ago
Asia’s Complex Compliance Landscapealmost 7 years ago
European Pricing Talks: A lot of Smoke—or is it Fire?almost 7 years ago
FDA Maps Pathway to More Accessible Biosimilarsalmost 7 years ago
Top Trends, Takeaways from DIAalmost 7 years ago
Pharma & Biotech: Financial Pulse-Check, OutlookAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5